Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
NCT ID: NCT00096616
Last Updated: 2013-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
113 participants
INTERVENTIONAL
2004-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combivent® CFC MDI
Albuterol HFA MDI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* non-smokers,
* diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,
* stable use of Beta agonist
* daily use of inhaled steroids for one year
Exclusion Criteria
* intubated within 5 years,
* asthma exacerbation within 6 weeks of trial,
* use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,
* participating in another interventional trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
620 South 20th Street, NHB 104
Birmingham, Alabama, United States
Cooper Green Hospital
Birmingham, Alabama, United States
Southern California Clinical Trials
Lakewood, California, United States
Boehringer Ingelheim Investigational Site
Palmdale, California, United States
Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado, United States
Norwalk Hospital
Norwalk, Connecticut, United States
University of Miami School of Medicine
Miami, Florida, United States
Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
Boehringer Ingelheim Investigational Site
Coeur d'Arlene, Idaho, United States
Boehringer Ingelheim Investigational Site
River Forest, Illinois, United States
Boehringer Ingelheim Investigational Site
Olathe, Kansas, United States
LSU MC-Sheveport
Shreveport, Louisiana, United States
Boehringer Ingelheim Investigational Site
Auburn, Maine, United States
Johns Hopkins Asthma & Allergy
Baltimore, Maryland, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Boehringer Ingelheim Investigational Site
Berlin, New Jersey, United States
Boehringer Ingelheim Investigational Site
Cherry Hill, New Jersey, United States
North Shore University Hospital
Manhasset, New York, United States
NYU School of Medicine
New York, New York, United States
Division of Pulmonary & Critical Care Medicine
Durham, North Carolina, United States
Wake Forest University, Center for Human Genomics
Winston-Salem, North Carolina, United States
Penn State University, Hershey Medical Center
Hershey, Pennsylvania, United States
Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
Spartanburg Medical Research
Spartanburg, South Carolina, United States
Ben Taul General Hospital
Houston, Texas, United States
University of Texas Health Center at Tyler
Tyler, Texas, United States
University of Wisconsin Hospital
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gelb AF, Karpel J, Wise RA, Cassino C, Johnson P, Conoscenti CS. Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. Pulm Pharmacol Ther. 2008 Aug;21(4):630-6. doi: 10.1016/j.pupt.2008.02.005. Epub 2008 Mar 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1012.50
Identifier Type: -
Identifier Source: org_study_id